Contents

Search

refractory anemia (RA)

Epidemiology: -> 28% of cases of myelodysplastic syndrome Pathology: 1) circulating blasts < 1% 2) bone marrow blasts < 5% 3) < 15% ringed sideroblasts in marrow 4) no Auer rods Management: -> prognosis: a) 0-20% (mean 11%) transformation to acute leukemia (AML) b) survival 19-64 months (mean 37 months)

Interactions

disease interactions

General

anemia myelodysplastic syndrome (MDS)

References

  1. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 677-78